Search
TC-2696
go.drugbank.com/drugs/DB05576ExperimentalSynonyms: 5-(5-METHOXY-3-PYRIDINYL)-N-METHYL-4-PENTEN-2-AMINE, (2S,4E)-VTP-201227
go.drugbank.com/drugs/DB05652ExperimentalVTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications. It is being developed by Vitae Pharmaceuticals.
Orbifloxacin
go.drugbank.com/drugs/DB11443ExperimentalVet approvedIt is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.
Basimglurant
go.drugbank.com/drugs/DB11833InvestigationalBasimglurant has been used in trials studying the diagnostic and treatment of Depression, Fragile X Syndrome, and Major Depressive Disorder.
ZD-6126
go.drugbank.com/drugs/DB11872InvestigationalZD6126 has been used in trials studying the treatment of Kidney Neoplasms, Colorectal Neoplasms, Metastases, Neoplasm, and Carcinoma, Renal Cell.
RC118
go.drugbank.com/drugs/DB18428InvestigationalRC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE.
Synonyms: Recombinant humanized anti-MSLN monoclonal antibody- monomethyl auristatin E conjugateGYM329
go.drugbank.com/drugs/DB18590InvestigationalGYM329 is a recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH-dependent manner
Synonyms: recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH dependent mannerTetraarsenic tetrasulfide
go.drugbank.com/drugs/DB19141InvestigationalTetraarsenic tetrasulfide is under investigation in clinical trial NCT05682131 (South China Children Cancer Group - Relapsed-acute Lymphoblastic Leukemia 2022 Protocol).
Substance P
go.drugbank.com/drugs/DB19198InvestigationalSubstance P is under investigation in clinical trial NCT03738878 (Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1).
TNP-2092
go.drugbank.com/drugs/DB16312InvestigationalTNP-2092 is under investigation in clinical trial NCT03964493 (TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection).